Batabulin

DB16103InvestigationalSmall molecule

Batabulin is under investigation in clinical trial NCT00057382 (T138067 Versus Doxorubicin in Chemotherapy-naive, Unresectable, Hepatocellular Carcinoma Patients).

Mechanism: Pharmacologically active on Tubulin beta chain and Tubulin
Curator reviewed
Formula / weight: C₁₃H₇F₆NO₃S · 371.25 g/mol (avg)
Code names: T-138067 · T-67 · TL-057

Resolves to

Compound

UNIIT4NP8G3K6QCAS195533-53-0ChEMBLCHEMBL79280

Structure

InChIKeyROZCIVXTLACYNY-UHFFFAOYSA-NSMILESCOC1=C(F)C=C(NS(=O)(=O)C2=C(F)C(F)=C(F)C(F)=C2F)C=C1

Targets

P07437TUBB

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Batabulin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account